Rapidly progressive glomerulonephritis laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 6: Line 6:


The most important step in managing rapidly progressive glomerulonephritis is rapid diagnosis. It is essential for organ preservation. Laboratory studies include,
The most important step in managing rapidly progressive glomerulonephritis is rapid diagnosis. It is essential for organ preservation. Laboratory studies include,
[[complete blood cell count]] (CBC) with differential, [[serum electrolytes]], BUN, [[creatinine]], [[lactate dehydrogenase]] (LDH), [[creatine phosphokinase]] (CPK), and [[liver function tests]]: The most common abnormality is an increased [[serum creatinine]] level. However, the level can be normal at presentation. Tissue enzyme (ie, LDH, CPK) levels may be elevated if there is significant muscle inflammation and [[myalgias]]. [[Urinalysis]] with microscopy usually show [[proteinuria]] but is rarely greater than 2-3 g in 24 hours. [[Microscopic hematuria]] may be  present and may be the only clue to renal disease at presentation. The presence of [[red cell casts]] indicates [[glomerulonephritis]] and is a very helpful clue. [[Erythrocyte sedimentation rate]] is usually elevated with active disease. [[C-reactive protein]] levels are elevated and correspond with disease activity. High [[antinuclear antibody]] (ANA) titer rises the suspicion toward [[systemic lupus erythematosus]]. More than 80% of patients with [[microscopic polyangiitis]] are ANCA-positive. The symptoms of [[cryoglobulinemia]] are very similar to those of ANCA-related disease. However, in persons with ANCA-related diseases, the [[cryoglobulin]] titer result should be negative. [[Hepatitis]] profile should be performed as hepatitis B is associated with [[polyarteritis nodosa]] and [[hepatitis C]] is associated with [[mixed cryoglobulinemia]]. Urine and serum [[protein electrophoresis]] is done in any middle-aged or elderly person presenting with rapidly progressive glomerulonephritis to exclude the presence of [[light-chain disease]] or noticeable [[multiple myeloma]] as a cause of the clinical findings.
[[complete blood cell count]] (CBC) with differential, [[serum electrolytes]], BUN, [[creatinine]], [[lactate dehydrogenase]] (LDH), [[creatine phosphokinase]] (CPK), and [[liver function tests]]: The most common abnormality is an increased [[serum creatinine]] level. However, the level can be normal at presentation. Tissue enzyme (ie, LDH, CPK) levels may be elevated if there is significant muscle inflammation and [[myalgias]]. [[Urinalysis]] with microscopy usually show [[proteinuria]] but is rarely greater than 2-3 g in 24 hours. [[Microscopic hematuria]] may be  present and may be the only clue to renal disease at presentation. The presence of [[red cell casts]] indicates [[glomerulonephritis]] and is a very helpful clue. [[Erythrocyte sedimentation rate]] is usually elevated with active disease. [[C-reactive protein]] levels are elevated and correspond with disease activity. High [[antinuclear antibody]] (ANA) titer rises the suspicion toward [[systemic lupus erythematosus]]. More than 80% of patients with [[microscopic polyangiitis]] are [[Anti-neutrophil cytoplasmic antibody|ANCA]]-positive. The symptoms of [[cryoglobulinemia]] are very similar to those of [[Anti-neutrophil cytoplasmic antibody|ANCA]]-related disease. However, in persons with [[Anti-neutrophil cytoplasmic antibody|ANCA]]-related diseases, the cryoglobulin titer result should be negative. [[Hepatitis]] profile should be performed as hepatitis B is associated with [[polyarteritis nodosa]] and [[hepatitis C]] is associated with [[Cryoglobulinemia|mixed cryoglobulinemia.]] Urine and serum [[protein electrophoresis]] is done in any middle-aged or elderly person presenting with rapidly progressive glomerulonephritis to exclude the presence of light-chain disease or noticeable [[multiple myeloma]] as a cause of the clinical findings.


==Laboratory Findings==
==Laboratory Findings==

Latest revision as of 14:29, 31 July 2018

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis laboratory findings

CDC on Rapidly progressive glomerulonephritis laboratory findings

Rapidly progressive glomerulonephritis laboratory findings in the news

Blogs on Rapidly progressive glomerulonephritis laboratory findings

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2] Nazia Fuad M.D.

Overview

The most important step in managing rapidly progressive glomerulonephritis is rapid diagnosis. It is essential for organ preservation. Laboratory studies include, complete blood cell count (CBC) with differential, serum electrolytes, BUN, creatinine, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), and liver function tests: The most common abnormality is an increased serum creatinine level. However, the level can be normal at presentation. Tissue enzyme (ie, LDH, CPK) levels may be elevated if there is significant muscle inflammation and myalgias. Urinalysis with microscopy usually show proteinuria but is rarely greater than 2-3 g in 24 hours. Microscopic hematuria may be present and may be the only clue to renal disease at presentation. The presence of red cell casts indicates glomerulonephritis and is a very helpful clue. Erythrocyte sedimentation rate is usually elevated with active disease. C-reactive protein levels are elevated and correspond with disease activity. High antinuclear antibody (ANA) titer rises the suspicion toward systemic lupus erythematosus. More than 80% of patients with microscopic polyangiitis are ANCA-positive. The symptoms of cryoglobulinemia are very similar to those of ANCA-related disease. However, in persons with ANCA-related diseases, the cryoglobulin titer result should be negative. Hepatitis profile should be performed as hepatitis B is associated with polyarteritis nodosa and hepatitis C is associated with mixed cryoglobulinemia. Urine and serum protein electrophoresis is done in any middle-aged or elderly person presenting with rapidly progressive glomerulonephritis to exclude the presence of light-chain disease or noticeable multiple myeloma as a cause of the clinical findings.

Laboratory Findings

Blood Work-Up

Laboratory findings

  • ESR and CRP may be elevated and indicate inflammation and activity of the disease.

Urine Work-Up

References

  1. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA; et al. (1985). "Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis". Lancet. 1 (8426): 425–9. PMID 2857806.
  2. Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF; et al. (1989). "Association between active Wegener's granulomatosis and anticytoplasmic antibodies". Arch Intern Med. 149 (11): 2461–5. PMID 2684074.
  3. Falk RJ, Hogan S, Carey TS, Jennette JC (1990). "Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network". Ann Intern Med. 113 (9): 656–63. PMID 2221646.
  4. Hricik DE, Chung-Park M, Sedor JR (1998). "Glomerulonephritis". N Engl J Med. 339 (13): 888–99. doi:10.1056/NEJM199809243391306. PMID 9744974.

Template:WH Template:WS